Douglas Lankler receives 194,883 Pfizer (NYSE: PFE) stock rights

Rhea-AI Filing Summary

Pfizer Inc. Executive Vice President Douglas M. Lankler reported an acquisition of 194,883 stock appreciation rights on March 3, 2026. These derivative awards carry no exercise price and are scheduled to be settled in Pfizer common stock on the fifth anniversary of the grant date, subject to vesting conditions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LANKLER DOUGLAS M

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		194,883		03/03/2031(1)	03/03/2031(1)	Common Stock	194,883	$0.0000	194,883	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for Douglas M. Lankler	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) report for Douglas M. Lankler?

Douglas M. Lankler received a grant of 194,883 stock appreciation rights from Pfizer. The Form 4 shows these derivative awards were acquired at a price of $0.00 per right and will ultimately be settled in shares of Pfizer common stock, subject to vesting conditions.

How many stock appreciation rights did Pfizer (PFE) grant in this Form 4?

Pfizer granted 194,883 stock appreciation rights to Executive Vice President Douglas M. Lankler. After this grant, the total reported derivative holdings from this award are 194,883 rights, which are scheduled to be settled in Pfizer common stock on the fifth anniversary of the grant date.

When will Douglas M. Lankler’s Pfizer (PFE) stock appreciation rights be settled?

The stock appreciation rights are expected to be settled on the fifth anniversary of the grant date. According to the footnote, once vesting requirements are met, settlement will occur in shares of Pfizer common stock rather than cash, aligning the award’s value with future stock performance.

What are stock appreciation rights in the context of Pfizer (PFE)’s Form 4 filing?

Stock appreciation rights give the holder value linked to Pfizer’s share price without upfront cost. In this filing, the rights were granted at $0.00 per right and, after vesting, are set to be settled in Pfizer common stock on the fifth anniversary of the grant date.

Does the Pfizer (PFE) Form 4 show a stock purchase or a compensation grant?

The filing reflects a compensation grant, not an open-market stock purchase. Douglas M. Lankler acquired 194,883 stock appreciation rights through a grant coded as a “Grant, award, or other acquisition,” with no cash price paid per right and future settlement in Pfizer common stock.